Leonardo DRS: Strong Backlog Meets Margin Pressure-Is the Moat Still Wide Enough?

The foundation of any compounding business is visible demand-and Leonardo DRS possesses one of the stronger backlog positions in defense electronics. At $8.7 billion, the year-end backlog provides multi-year revenue visibility that most peers simply cannot match. For a value investor, this is the bedrock: a pipeline of confirmed work that insulates against cyclical downturns and creates a predictable path to revenue conversion.

What makes this backlog meaningful is not just its size, but the consistency of demand that built it. DRS has achieved a book-to-bill ratio of 1.2 or better for four consecutive years-a disciplined indicator that new orders consistently outpace shipments. This is not a spike driven by a single contract, but a sustained pattern of customer commitment across geographies and programs. In the defense electronics space, where program timelines stretch across decades, this consistency signals a competitive moat that is actively widening.

The revenue conversion validates the quality of that backlog. Full-year revenue reached $3.6 billion, reflecting 13% organic growth-a result of the backlog converting rather than one-time wins. Advanced Sensing & Computing grew 11%, while Integrated Mission Systems accelerated to 15%, driven by electric propulsion and counter-UAS programs. These are not marginal gains; they represent structural demand in high-growth defense domains where DRS has invested for years.

For the long-term investor, the implication is clear: DRS has built a demand engine that operates independently of quarterly sentiment. The backlog provides a floor under revenue, while the book-to-bill trend suggests the ceiling keeps rising. In a market obsessed with near-term earnings, this visibility is itself a competitive advantage-and a prerequisite for the kind of compounding that defines value investing.

Supply-Side Constraints: Margin Erosion Risks

Strong revenue growth means little if profitability fails to keep pace-and this is where Leonardo DRS faces its most pressing challenge. The company delivered 13% organic revenue growth in 2025, yet adjusted EBITDA margin came in at 12.4%, flat year-over-year. For a business with a wide competitive moat, we expect margins to expand or at minimum hold steady as scale benefits kick in. Instead, DRS is experiencing a divergence that demands scrutiny.

The Q4 margin of 14.9% offers a sliver of optimism-it suggests the full-year result was not a floor but a midpoint. Adjusted EBITDA grew 7% in Q4, tracking revenue growth more closely than in prior periods. Yet the full-year picture remains concerning: revenue rose 13%, but earnings did not. This is the classic symptom of cost pressures outpacing pricing power.

Two forces are squeezing margins. First, material cost inflation continues to press on the business, particularly in the Advanced Sensing & Computing segment where supply chain constraints have been persistent. While management notes that germanium supply constraints are now "contained," the damage to 2025 margins was already done. Second, and more significant from a compounding perspective, is the surge in investment spending. Internal R&D investment increased 40% in 2025, targeted at high-growth areas including airborne, missiles, space, and unmanned systems. Capital expenditures rose over 60%, focused on the Charleston naval power facility and tactical radar capacity.

From a value investing standpoint, the question is whether this is disciplined investment in future moat-building or defensive spending merely to maintain competitive position. The 40% R&D increase is substantial-and management frames it as targeting high-growth domains where DRS has already demonstrated winning capability. The Charleston expansion will increase production capacity for naval power systems, enabling modular manufacturing across multiple ship classes. These are not trivial investments; they represent a deliberate choice to sacrifice near-term margins for long-term positioning.

Yet the market is not being compensated for this risk. Operating margin of approximately 9.4% sits below peer averages and below DRS's own five-year historical average. For a business that claims a wide moat, this is a red flag. Moats exist to protect profitability-not to justify margin compression while competitors hold steady. The 12.4% adjusted EBITDA margin is acceptable, but it is not exceptional, and it does not reflect the kind of operating leverage we expect from a compounding franchise.

The path forward hinges on whether these investments convert into margin expansion in 2026 and beyond. Management's guidance projects 70-90 basis points of margin improvement, driven by Columbia-class program profitability and favorable mix. If realized, this would signal that the 2025 investment surge was indeed a deliberate inflection point rather than structural erosion. But until that improvement materializes, the margin story remains a question mark-and for the value investor, question marks are themselves a cost.

Valuation and Investment Considerations

The stock has run significantly higher-up 38% year-to-date and 65.9% over the rolling twelve months-trading now at $47.10, just shy of its 52-week high of $49.31. For a value investor, this raises an immediate question: does the current price offer a margin of safety, or has the market already priced in perfection?

The valuation metrics present a mixed picture. The trailing P/E sits at 45x, while the forward P/E jumps to 60x-substantially above market averages. EV/EBITDA of 27.7x also commands a premium, though the EV/sales multiple of 3.35x is more moderate. This divergence tells a story: the market is paying up for near-term earnings growth and quality, not for sales scale. The forward multiple in particular suggests investors expect sustained margin expansion to justify the premium.

This is where the margin story from earlier becomes critical. A forward P/E of 60x implies confidence that 2025's 12.4% EBITDA margin will improve meaningfully-and that the 70-90 basis points of projected improvement will materialize. If management delivers, the current multiple could prove reasonable. If margins stagnate or compress further, the stock faces multiple contraction risk.

The dividend profile reinforces the growth-oriented narrative. At 0.76% yield with a 34% payout ratio, DRS is clearly prioritizing reinvestment over income distribution. The low payout ratio leaves room for dividend growth, but the minimal yield offers little compensation for equity risk in the near term. For a value investor seeking compounding, this is acceptable only if the retained earnings generate strong returns-and that circles back to the margin question.

What matters for the long-term holder is whether the current price reflects intrinsic value given the demand and supply dynamics we've examined. The backlog provides a strong floor, but the elevated multiples leave little room for execution misses. The margin of safety, if it exists, lies in the gap between the current price and what the business could deliver if margins recover as projected. That gap is narrow.

The stock is not cheap by traditional value metrics. Yet for investors who believe in the moat's durability and management's ability to convert investment into margin expansion, the current price may be justified-provided they have the patience to wait for the compounding to materialize. For now, the valuation demands execution. The margin story, not the backlog, will determine whether this premium holds.

Catalysts and Risks to Monitor

For a value investor, the premium valuation demands vigilant monitoring of the specific catalysts and risks that will determine whether Leonardo DRS compounding story plays out-or falters. The backlog provides visibility, but the margin trajectory hinges on several material factors that could swing the thesis either way.

Contract awards and backlog conversion remain the primary demand catalyst. The $8.7 billion year-end backlog provides multi-year revenue visibility, but the book-to-bill ratio of 1.2 or better for four consecutive years is the more meaningful indicator. This pattern reflects sustained customer commitment across geographies and programs-not one-time wins. Investors should track whether this trend continues into 2026, as new funded awards signal whether the moat is widening or merely holding steady. The recent SDA Tracking Layer Tranche 3 space program win enhances presence in the space market, adding to the pipeline.

Material cost trajectories present the most immediate margin risk. In 2025, material cost pressures squeezed the 12.4% adjusted EBITDA margin flat year-over-year despite 13% revenue growth. Germanium supply constraints are now "contained", but Q1 2026 guidance projects adjusted EBITDA margin in the "low 11% range"-below the full-year 2025 result. This suggests material cost headwinds persist even as revenue scales. For a value investor, the question is whether this represents temporary turbulence or structural pressure that erodes the moat's profitability protection.

Government budget cycles and political risk represent a structural dependency. DRS relies heavily on US Department of Defense spending, and while FY2026 defense budget increases and higher NATO spending commitments provide near-term tailwinds, the long-term picture depends on political continuity. Government audits and contract disputes-such as the legacy surveillance program conclusion that resulted in a one-off loss-can create unexpected volatility. The value investor must account for the fact that defense demand is not purely commercial; it is subject to fiscal policy shifts and procurement priorities that can change with administrations.

R&D investment maturation offers the key upside catalyst. Management increased internal R&D spending 40% in 2025, targeting high-growth domains including airborne, missiles, space, and unmanned systems. 2026 adjusted EBITDA guidance projects 70-90 basis points of margin improvement, driven by Columbia-class program profitability and favorable mix. If these investments convert into margin expansion as projected, the current premium becomes justified. If they fail to materialize, the stock faces multiple contraction risk. This is the critical inflection point to watch.

The path forward is clear: the backlog provides a strong floor, but margin recovery is the variable that determines whether this compounding franchise delivers. For the patient value investor, these monitoring points are not reasons to avoid the stock-they are the specific metrics that will confirm or contradict the thesis over the coming quarters. The margin of safety lies in execution, and execution is visible through these catalysts.